Everyone showed up except the diagnosis

January 7: OpenAI launches ChatGPT Health. January 11: Anthropic releases Claude for Healthcare. January 13: Google ships MedGemma 1.5. Three companies. One week. Same sector.

Then the second wave hit. March 10: Amazon Health AI goes live for every user of the Amazon app, shipping five ready-to-deploy agents. Same day, Salesforce releases six Agentforce agents for healthcare. March 12: Microsoft launches Copilot Health, connecting to Apple Health, Oura, and 50,000 EHR-connected hospitals. Oracle's Clinical AI Agent starts drafting orders across thirty specialities via ambient listening. IBM partners with Deepgram on voice AI. Nvidia expands healthcare imaging partnerships.

Nine of the world's largest technology companies. Seventy-two days. One industry.

That's not a trend. It's a land grab.

Every single launch prioritises the same thing: administrative support. Explaining lab results. Managing appointments. Navigating insurance. Automating documentation. Not one of them claims to diagnose. This isn't a gap in the product roadmap. It IS the product roadmap.

The trillion-dollar front door

The US spends roughly $1 trillion a year on healthcare administration. That's the beachhead. Scheduling, prior authorisations, clinical coding, referral routing: expensive, high-volume, error-prone tasks that AI handles well. And they sit safely outside the regulatory and liability perimeter surrounding anything clinical.

Half of US physicians already use AI professionally, double the figure from 2023. But "using AI" overwhelmingly means documentation, summaries and search. Not differential diagnosis. Not clinical reasoning.

Amazon's One Medical CMO put it in a single phrase this week: "AI is the front door to healthcare." Not the operating theatre. Not the diagnostic suite. The front door. Mustafa Suleyman, CEO of Microsoft AI, went further. He called Copilot Health "first steps towards a medical superintelligence." That's a bold claim for a product that, right now, reads your Oura ring data and explains what your LDL cholesterol means.

Every company frames admin differently. Amazon ships five agents covering patient verification, scheduling, clinical documentation, billing and prescriptions. Microsoft aggregates your wearable data, lab results and medical records into one view, then explains them in plain language. Salesforce automates referrals, eligibility checks and care gap coordination. Different packaging, identical instinct: go where the liability isn't.

Who didn't show up

The absences say as much as the launches. Meta has no first-party healthcare product; its open-source model Llama powers third-party clinical tools, but Meta itself isn't building anything clinical. Tesla: zero presence. Samsung has the hardware (Galaxy Ring, Galaxy Watch) and even acquired clinical platform Xealth last year, but didn't join the AI launch wave. The Chinese tech giants (Tencent, ByteDance, Alibaba) dominate healthcare AI at home but have zero deployed products in Western markets.

Then there's Apple. Quietly the most powerful player in the room, and the only one not competing in the race everyone else is running. Apple Health is the universal data aggregation layer. Microsoft, OpenAI and Anthropic all plug into it. Apple supplies the pipes; everyone else builds the interface on top. It's a position of structural power that requires no AI agent and no regulatory filing. If Apple ever builds its own health AI on top of that layer, every company that just launched will discover they've been building on someone else's platform.

The pattern underneath

Every company is racing to own the patient's longitudinal health record: a single AI-readable layer combining wearables, EHRs, lab results and consumer data. Harvard's Arjun Manrai calls 2026 "the year of context." Whoever controls that layer controls the relationship.

But controlling the relationship and making a clinical call are different things entirely. STAT News raised the question at HIMSS last week: these agents are deploying faster than anyone is validating them. CB Insights predicts that competition between OpenAI and Anthropic will inflate valuations for startups holding proprietary clinical datasets and regulatory clearances: assets that grow more valuable precisely because the large players won't touch them.

The pattern repeats across all the launches. ✅ Ask the AI what your glucose spike means: yes. ❌ Ask it whether that spike, combined with your family history, means you should get screened for diabetes: silence. Every product routes you back to your doctor at exactly the point where the question gets clinical.

The question that matters isn't who builds the best health assistant. It's who crosses the line into diagnosis first. Until someone does, the most advanced AI in healthcare will keep doing what it does today: explaining your blood work in plain English and booking your follow-up.

💥 May this inspire you to look past the launches and ask what's still missing.